A retrospective analysis of practical benefits and caveats of the new WHO 2021 central nervous system tumor classification scheme in low‐resource settings: “A perspective from low‐ and middle‐income countries”
Neuropathology · 2024-06 · 44 (3) · 183-189
DOI: 10.1111/neup.12953 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuropathology, online erschienen am 29.11.2023. Verfasst von Yazgı Köy und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Batman Teaching and Research Hospital, Batman, Turkey. Hauptthemen laut MEDLINE: World Health Organization, Central Nervous System Neoplasms, Developing Countries. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
The revised classification of tumors of the central nervous system (CNS) by the World Health Organization (WHO) in 2021 was hailed as a major advance and improvement in the management of brain tumor patients. However, the increased reliance on sophisticated technology and molecular analysis posed a major challenge to healthcare systems in low‐ and middle‐income countries. A few recent publications have drawn attention to the issue of the applicability of the new CNS WHO 2021 worldwide, but the exuberant enthusiasm observed in high‐income countries seems to have stifled such a concern. In this study, we present data on the practical utility of the changes that occurred in CNS WHO 2021 in four institutions with limited resources. Our findings demonstrate no major alterations in patient management in low resource settings and significant added financial impact. While there is no doubt that the revised classification provides greater insight into tumor biology and molecular/genetic features of CNS tumors, its practical benefit and applicability in the majority of cases worldwide are limited, and attempts to improve its utility in low resource settings are warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology, Batman Teaching and Research Hospital, Batman, Turkey.
- Department of Pathology, Atatürk University School of Medicine, Erzurum, Turkey.
- Department of Pathology, Katip Çelebi University Atatürk Teaching and Research Hospital, Izmir, Turkey.
- Department of Pathology, Gaziantep University Şahinbey Teaching and Research Hospital, Gaziantep, Turkey.
- Department of Pathology, UCSF School of Medicine, San Francisco, California, USA.
ORCID-Profile: Yazgı Köy
Zitieren
APA
Köy, Y., Ceylan, O., Kahraman, A., Cangi, S., Özmen, S., & Tihan, T. (2024). A retrospective analysis of practical benefits and caveats of the new WHO 2021 central nervous system tumor classification scheme in low‐resource settings: “A perspective from low‐ and middle‐income countries”. Neuropathology, 44(3), 183-189. https://doi.org/10.1111/neup.12953
Vancouver
Köy Y, Ceylan O, Kahraman A, Cangi S, Özmen S, Tihan T. A retrospective analysis of practical benefits and caveats of the new WHO 2021 central nervous system tumor classification scheme in low‐resource settings: “A perspective from low‐ and middle‐income countries”. Neuropathology. 2024;44(3):183-189. doi:10.1111/neup.12953
BibTeX
@article{Ky2024,
author = {Köy, Yazgı and Ceylan, Onur and Kahraman, Aslı and Cangi, Sibel and Özmen, Sevilay and Tihan, Tarık},
title = {A retrospective analysis of practical benefits and caveats of the new WHO 2021 central nervous system tumor classification scheme in low‐resource settings: “A perspective from low‐ and middle‐income countries”},
journal = {Neuropathology},
year = {2024},
volume = {44},
number = {3},
pages = {183--189},
doi = {10.1111/neup.12953}
}
EUVIMED